Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Carlos Roncero & F Javier Álvarez. (2014) The use of lisdexamfetamine dimesylate for the treatment of ADHD and other psychiatric disorders. Expert Review of Neurotherapeutics 14:8, pages 849-865.
Read now
Read now
James Ermer, Mary B Haffey, Cynthia Richards, Kenneth Lasseter, Ben Adeyi, Mary Corcoran, Beverly Stanton & Patrick Martin. (2013) Double-blind, placebo-controlled, two-period, crossover trial to examine the pharmacokinetics of lisdexamfetamine dimesylate in healthy older adults. Neuropsychiatric Disease and Treatment 9, pages 219-229.
Read now
Read now
Ann C Childress & Floyd R Sallee. (2012) The use of lisdexamfetamine dimesylate for the treatment of ADHD. Expert Review of Neurotherapeutics 12:1, pages 13-26.
Read now
Read now
Josephine Elia, Zoe Wilson, Lilly Sehgal La Porta, Sibel A Algon, Matthew L Prowler, Shanique T Cartwright, Patricia A McKenna, Seth Laracy, Toshinobu Takeda & Karin Borgmann-Winter. (2011) Methylphenidate transdermal system: clinical applications for attention-deficit/hyperactivity disorder. Expert Review of Clinical Pharmacology 4:3, pages 311-328.
Read now
Read now
Michael Pennick. (2010) Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatric Disease and Treatment 6, pages 317-327.
Read now
Read now
Articles from other publishers (20)
Ana Y. Simão, Mónica Antunes, Hernâni Marques, Tiago Rosado, Sofia Soares, Joana Gonçalves, Mário Barroso & Eugenia Gallardo. 2022. Handbook of Substance Misuse and Addictions. Handbook of Substance Misuse and Addictions
2003
2027
.
Ana Y. Simão, Mónica Antunes, Hernâni Marques, Tiago Rosado, Sofia Soares, Joana Gonçalves, Mário Barroso & Eugenia Gallardo. 2021. Handbook of Substance Misuse and Addictions. Handbook of Substance Misuse and Addictions
1
25
.
Georgios Schoretsanitis, Jose de Leon, Chin B. Eap, John M. Kane & Michael Paulzen. (2019) Clinically Significant Drug–Drug Interactions with Agents for Attention-Deficit/Hyperactivity Disorder. CNS Drugs 33:12, pages 1201-1222.
Crossref
Crossref
John S. MarkowitzKennerly S. Patrick. (2017) The Clinical Pharmacokinetics of Amphetamines Utilized in the Treatment of Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology 27:8, pages 678-689.
Crossref
Crossref
Patrick C. Dolder, Petra Strajhar, Patrick Vizeli, Felix Hammann, Alex Odermatt & Matthias E. Liechti. (2017) Pharmacokinetics and Pharmacodynamics of Lisdexamfetamine Compared with D-Amphetamine in Healthy Subjects. Frontiers in Pharmacology 8.
Crossref
Crossref
Eloisa Comiran, Félix Henrique Kessler, Pedro Eduardo Fröehlich & Renata Pereira Limberger. (2016) Lisdexamfetamine: A pharmacokinetic review. European Journal of Pharmaceutical Sciences 89, pages 172-179.
Crossref
Crossref
James C. Ermer, Michael Pennick & Glen Frick. (2016) Lisdexamfetamine Dimesylate: Prodrug Delivery, Amphetamine Exposure and Duration of Efficacy. Clinical Drug Investigation 36:5, pages 341-356.
Crossref
Crossref
James E. Frampton. (2016) Lisdexamfetamine: A Review in ADHD in Adults. CNS Drugs 30:4, pages 343-354.
Crossref
Crossref
James Ermer, Mary Corcoran & Patrick Martin. (2015) Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. Drugs in R&D 15:2, pages 175-185.
Crossref
Crossref
David R. Coghill, Beatriz Caballero, Shaw Sorooshian & Richard Civil. (2014) A Systematic Review of the Safety of Lisdexamfetamine Dimesylate. CNS Drugs 28:6, pages 497-511.
Crossref
Crossref
Frank A. López & Jacques R. Leroux. (2013) Long-acting stimulants for treatment of attention-deficit/hyperactivity disorder: a focus on extended-release formulations and the prodrug lisdexamfetamine dimesylate to address continuing clinical challenges. ADHD Attention Deficit and Hyperactivity Disorders 5:3, pages 249-265.
Crossref
Crossref
Lily HechtmanJosephine EliaRichard Kingsley, Christopher Lam, Toshinobu Takeda, Rachel de Berardinis, Seth Laracy, Jillan Sackett, Shih-Ching Tang, Martin Schardt, Kristina Nivus, Hakon Hakonarson & Sibel Algon. 2013. Clinical Management of Attention Deficit Hyperactivity Disorder. Clinical Management of Attention Deficit Hyperactivity Disorder
72
102
.
Thomas Babcock, Bryan Dirks, Ben Adeyi & Brian Scheckner. (2012) Efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration study. BMC Pharmacology and Toxicology 13:1.
Crossref
Crossref
Christopher Steer, Jan Froelich, César A. Soutullo, Mats Johnson & Monica Shaw. (2012) Lisdexamfetamine Dimesylate. CNS Drugs 26:8, pages 691-705.
Crossref
Crossref
James C. Ermer, Mary B. Haffey, Walter J. Doll, Patrick Martin, Erik P. Sandefer, Kerry Dennis, Mary Corcoran, Laura Trespidi & Richard C. Page. (2012) Pharmacokinetics of Lisdexamfetamine Dimesylate after Targeted Gastrointestinal Release or Oral Administration in Healthy Adults. Drug Metabolism and Disposition 40:2, pages 290-297.
Crossref
Crossref
M. NguyenM.A. ShapiroS. Tharani. (2012) Clinical Utility of Lisdexamfetamine for the Management of Attention-Deficit Hyperactivity Disorder. Clinical Medicine Insights: Therapeutics 4, pages CMT.S8706.
Crossref
Crossref
Gabriel Kaplan & Jeffrey H. Newcorn. (2011) Pharmacotherapy for Child and Adolescent Attention-deficit Hyperactivity Disorder. Pediatric Clinics of North America 58:1, pages 99-120.
Crossref
Crossref
James C. Ermer, Ben A. Adeyi & Michael L. Pucci. (2010) Pharmacokinetic Variability of Long-Acting Stimulants in the Treatment of Children and Adults with Attention-Deficit Hyperactivity Disorder. CNS Drugs 24:12, pages 1009-1025.
Crossref
Crossref
Gregory Mattingly. (2014)
Lisdexamfetamine Dimesylate:
A Prodrug Stimulant for the Treatment of ADHD in Children and Adults
. CNS Spectrums 15:5, pages 315-325.
Crossref
Crossref
Samuel W. Boellner, Jeffrey G. Stark, Suma Krishnan & Yuxin Zhang. (2010) Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: A single-dose, randomized, open-label, crossover study. Clinical Therapeutics 32:2, pages 252-264.
Crossref
Crossref